Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
W Gao, X Wang, Y Zhou, X Wang, Y Yu - Signal transduction and …, 2022 - nature.com
In recent years, immunotherapy represented by immune checkpoint inhibitors (ICIs) has led
to unprecedented breakthroughs in cancer treatment. However, the fact that many tumors …
to unprecedented breakthroughs in cancer treatment. However, the fact that many tumors …
Targeted therapy for non‐small‐cell lung cancer: New insights into regulated cell death combined with immunotherapy
S Li, A Wang, Y Wu, S He, W Shuai… - Immunological …, 2024 - Wiley Online Library
Non‐small‐cell lung cancer (NSCLC), which has a high rate of metastatic spread and drug
resistance, is the most common subtype of lung cancer. Therefore, NSCLC patients have a …
resistance, is the most common subtype of lung cancer. Therefore, NSCLC patients have a …
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open …
Background In the primary analysis of CheckMate 9ER, nivolumab plus cabozantinib
showed superior progression-free survival, overall survival, and objective response over …
showed superior progression-free survival, overall survival, and objective response over …
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib …
Background Results from the phase 3 CLEAR study showed that lenvatinib plus
pembrolizumab improved progression-free survival and overall survival compared with …
pembrolizumab improved progression-free survival and overall survival compared with …
Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective
R Murphy, S Halford, SN Symeonides - Frontiers in Oncology, 2023 - frontiersin.org
Modern cancer therapeutics are increasingly targeted, bringing the promise of new and
improved activity, alongside better tolerability. However, while many are indeed resulting in …
improved activity, alongside better tolerability. However, while many are indeed resulting in …
Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review
AKA Lalani, DYC Heng, NS Basappa… - Therapeutic …, 2022 - journals.sagepub.com
Background: Renal cell carcinoma (RCC) is a common malignancy with approximately 30%
of cases diagnosed at the advanced or metastatic stage. While single-agent vascular …
of cases diagnosed at the advanced or metastatic stage. While single-agent vascular …
[HTML][HTML] The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine
X Li, M Li, M Huang, Q Lin, Q Fang, J Liu… - Biomedicine & …, 2022 - Elsevier
Clinically, cancer drug therapy is still dominated by chemotherapy drugs. Although the
emergence of targeted drugs has greatly improved the survival rate of patients with …
emergence of targeted drugs has greatly improved the survival rate of patients with …
First and second-line treatments in metastatic renal cell carcinoma
Background and objective The treatment landscape for metastatic renal cell carcinoma
(mRCC) has evolved significantly in recent years, leading to improved outcomes. The aim of …
(mRCC) has evolved significantly in recent years, leading to improved outcomes. The aim of …
Immunologic tumor microenvironment modulators for turning cold tumors hot
GR Khosravi, S Mostafavi, S Bastan… - Cancer …, 2024 - Wiley Online Library
Tumors can be classified into distinct immunophenotypes based on the presence and
arrangement of cytotoxic immune cells within the tumor microenvironment (TME). Hot …
arrangement of cytotoxic immune cells within the tumor microenvironment (TME). Hot …
Single-cell sequencing and bulk RNA data reveal the tumor microenvironment infiltration characteristics of disulfidptosis related genes in breast cancer
Y Chen, C Jin, J Cui, Y Diao, R Wang, R Xu… - Journal of Cancer …, 2023 - Springer
Background Immunotherapy, represented by immune checkpoint inhibitors, has made
significant progress in the treatment of cancer. Numerous studies have demonstrated that …
significant progress in the treatment of cancer. Numerous studies have demonstrated that …